Cipaglucosidase Alfa PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2359727-71-0
Molecular formula
C4489H6817N1197O1298S32
Molecular weight
99350 g/mol
Drug class
Recombinant human acid alpha-glucosidaseenzyme replacement therapy biologic
Mechanism of action
Replaces deficient lysosomal acid alpha-glucosidase (GAA), enabling lysosomal hydrolysis of glycogen to glucose. The product is used with miglustat, which helps stabilise the enzyme and support cellular uptake.
Indications / reported uses
Long-term enzyme replacement therapy in adults with late-onset Pompe disease (GAA deficiency), in combination with miglustat, under the applicable product authorisation
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cipaglucosidase Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cipaglucosidase Alfa Permitted Daily Exposure (PDE) report (the Cipaglucosidase Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cipaglucosidase Alfa Occupational Exposure Limit (OEL) report (the Cipaglucosidase Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.